Embracing the New Era in Reducing CVD Residual Risk Beyond Statin Therapy

Embracing the New Era in Reducing CVD Residual Risk Beyond Statin Therapy
To register for this meeting, click on the ENROLL button. Login using your ReachMD credentials, or create a new Medtelligence / ReachMD account. ...more
  • Meeting date: 24 April, 2019
  • Meeting time: 06:00 PM - 08:15 PM PDT
  • Meeting location: JW Marriott Los Angeles
  • Meeting address: 900 W. Olympic Boulevard, Los Angeles, California, United States
  • Meeting contact:
  • Location website: JW Marriott Los Angeles
  • Overview

    In response to multiple surveys of endocrinologists and other healthcare providers managing patients with diabetes, there continues to exist a health care gap in reducing residual cardiovascular (CV) disease risk among these patients. There is a clear need to develop educational activities directed to physicians to discuss the current state of science, provide information on future potentially beneficial therapeutic targets, and apply appropriate clinical approaches to managing blood glucose and CV disease risk in patients with T2DM. Finally, there is a gap in understanding how the appropriate use of new agents might be used effectively in diabetes treatment plans.

Facebook Comments

Sign-up for the Medtelligence's newsletters.
Comprehensive Cardiology Education.

Better education for a better you.

* Required

We’re glad to see you’re enjoying Medtelligence…
but how about a more personalized experience?

Register for free